SHENZHEN HAIBIN PHARMACEUTICAL CO.,LTD

2003 SHAYAN ROAD, YANTIAN, SHENZHEN
SHENZHEN , 518081
China

Tel: 0086-75525225349
Fax: 0086-75525224692

Contact: Lindsey Chen

Email:

Type of Business:

Manufacturer, Exporter

Employees:

400

Year Established:

1989

Certification:

GMP, USP

Annual Sales Volume:

$25M to $74M

Export Percentage:

61-80%

Annual Purchasing Volume:

$1M to $5M

Contract Manufacturing:

OEM Services, ODM Services, Buyer Labels Offered

Ownership Type:

Limited Liability Company (LLC)

Registered Capital:

$51M to $100M

Bank Ref:

TO BE INFORMED

Harmonized System Codes:

3006

Business Message

Shenzhen Haibin is the first company who has GMP and produces Meropenem worldwide besides the originator. With 8 years production experience, Shenzhen Haibin has exported both Meropenem and Imipenem+Cilastatin to more than 30 countries.

Shenzhen Haibin devotes itself to R&D and production of carbapenem antibiotics. With dedicated workshop, 2 tons/month as capacity, best quality, most competitive price, professional and considerate service, Shenzhen Haibin has become the biggest manufacturer and exporter for Meropenem globally except AstraZeneca. Each year, there are lots of customers worldwide visiting us and even big multinational companies are quite interested in our product and approve Haibin as its qualified supplier after audit.

Shenzhen Haibin is the only company who produces carbapenem antibiotics from the beginning to the end: from its own starting material 4AA, 4BMA, MAP, Protected Meropenem, Crude Meropenem, Meropenem Trihydrate, Imipenem+Cilastatin to the Final Dosage Form. A full production chain and strong R&D team make Haibin always competitive in the market.

Aiming at regulated market after patent expiries, Shenzhen Haibin is establishing another brand-new workshop for Meropenem API and dosage form. DMF for unregulated and semi-regulated market has been available while for EU and USA market it will be ready by the end of 2010.

Meropenem and Imipenem are new antibiotics for severe infections. Total yearly consumption worldwide for both the products is increasing by 30% in the last 5 years by IMS data. Still more countries and more population are getting to know and begin to use the product. If you are developing this product now, please contact with us to get more information regarding it. If you haven’t started with this product, we would like to recommend you to launch this product as a new profit driver for your company.

If you need any information, please don’t hesitate to contact with us at any time.

With best regards